HIGH EFFICACY OF THE COMBINATION CHEMOTHERAPY (CT) OF ORAL VINORELBINE (NVBO) AND CAPECITABINE (X) WITH TRASTUZUMAB (H) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): UPDATED ANALYSIS OF THE RESULTS OF AN INTERNATIONAL PHASE II TRIAL

被引：0
|
作者：
Chan, A. [1 ]
Ganju, V. [2 ]
Becquart, D. [3 ]
Conte, P. [4 ]
Gil, M. Gil [5 ]
Petruzelka, L. [6 ]
Bernardo, G. [7 ]
Villanova, G. [8 ]
Tubiana-Mathieu, N. [9 ]
机构：
[1] Mt Hosp, Perth, WA, Australia
[2] Frankston Hosp, Melbourne, Vic, Australia
[3] AZ Middelheim, Med Oncol, Antwerp, Belgium
[4] Univ Modena, Univ Hosp, Dept Onc & Hem, I-41100 Modena, Italy
[5] ICO Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain
[6] Gen Fac Hosp, Prague 2, Czech Republic
[7] Fdn S Maugeri, Pavia, Italy
[8] Pierre Fabre Med, Med Affairs Onclo, Boulogne Billancourt, France
[9] CHU Dupuytren, Limoges, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [21] Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC).
    De Wit, M
    Harbeck, N
    Thomssen, C
    Becker, K
    Psonka, A
    Hoffmann, R
    Villena, C
    Schutte, M
    Hossfeld, DK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 84S - 84S
  • [22] All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Majois, F.
    Espie, M.
    Morand, M.
    Vaissiere, N.
    Villanova, G.
    Conte, P-F
    CANCER RESEARCH, 2009, 69 (02) : 385S - 385S
  • [23] Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer: A phase II trial
    Li, Qiao
    He, Maiyue
    Liu, Jiaxuan
    Wang, Zijing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] AN INTERNATIONAL PHASE II STUDY OF AN ALL-ORAL COMBINATION OF ORAL VINORELBINE (NVBO) AND CAPECITABINE (X) IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): LATEST RESULTS WITH A MEDIAN FOLLOW-UP OF 33.5 MONTHS
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Majois, F.
    Espie, M.
    Llombart, A.
    Villanova, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 68 - 68
  • [25] Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer
    Kalinsky, Kevin
    Chi, Dow-Chung
    Lee, Shing Mirn
    Adelson, Kerin B.
    Crew, Katherine D.
    Chuang, Ellen
    Makower, Della
    Hershman, Dawn L.
    Califano, Andrea
    Silva, Jose
    Maurer, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
    Chen, Tom Wei-Wu
    Yeh, Dah-Cherng
    Chao, Tsu-Yi
    Lin, Ching-Hung
    Chow, Louis Wing-Cheong
    Chang, Dwan-Ying
    Hsieh, Yao-Yu
    Huang, Shu-Min
    Cheng, Ann-Lii
    Lu, Yen-Shen
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (03) : 242 - 247
  • [27] A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer
    Lucas Bayo-Calero, Juan
    Mayordomo, Jose I.
    Salnchez-Rovira, Pedro
    Perez-Carrion, Ramon
    Illaramendi, Jose J.
    Garcia-bueno, Jose M.
    Gonzalez-Flores, Encarnacion
    Crespo, Carmen
    Ramos-Vazquez, Manuel
    Garcia-Palomo, Andres
    Ruiz-Borrego, Manuel
    de la Haba, Juan
    Gomez-Bernal, Amalia
    Yubero-Esteban, Alfonso
    CLINICAL BREAST CANCER, 2008, 8 (03) : 264 - 268
  • [28] Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Peacock, N. W.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Greco, F. A.
    Farley, C.
    Webb, C.
    Spigel, D. R.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Conte, P-F
    Majois, F.
    Espie, M.
    Morand, M.
    Vaissiere, N.
    Villanova, G.
    BRITISH JOURNAL OF CANCER, 2009, 101 (02) : 232 - 237
  • [30] All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
    N Tubiana-Mathieu
    P Bougnoux
    D Becquart
    A Chan
    P-F Conte
    F Majois
    M Espie
    M Morand
    N Vaissiere
    G Villanova
    British Journal of Cancer, 2009, 101 : 232 - 237
12345